Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab

PURPOSE: We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissue can predict effectiveness of bevacizumab added to capecitabine and oxaliplatin (CAPEOX) in patients with metastatic colorectal cancer (mCRC). EXPERIMENTAL DESIGN: Patients with mCRC treated with first line CAPEO...

Descripción completa

Detalles Bibliográficos
Autores principales: Boisen, Mogens K., Dehlendorff, Christian, Linnemann, Dorte, Nielsen, Boye S., Larsen, Jim S., Østerlind, Kell, Nielsen, Svend E., Tarpgaard, Line S., Qvortrup, Camilla, Pfeiffer, Per, Holländer, Niels H., Keldsen, Nina, Hansen, Torben F., Jensen, Brita B., Høgdall, Estrid V. S., Jensen, Benny V., Johansen, Julia S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198118/
https://www.ncbi.nlm.nih.gov/pubmed/25329796
http://dx.doi.org/10.1371/journal.pone.0109430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198118/
https://www.ncbi.nlm.nih.gov/pubmed/25329796
http://dx.doi.org/10.1371/journal.pone.0109430

Ejemplares similares